Brief: Shield Therapeutics Announces Positive Results In Pediatric Trial
Oct 1 (Reuters) - Shield Therapeutics PLC STXS.L: SHIELD THERAPEUTICS - POSITIVE EFFICACY AND TOLERANCE IN PEDIATRIC TRIAL SHIELD THERAPEUTICS PLC - SIGNIFICANT HB IMPROVEMENTS OBSERVED IN TRIAL GROUPS SHIELD THERAPEUTICS PLC - NO DISCONTINUATIONS IN FERRIC MALTOL GROUP DUE TO ADVERSE EVENTS SHIELD THERAPEUTICS PLC - NO SERIOUS ADVERSE EVENTS REPORTED IN TRIAL GROUPS Source text: ID:nRSA5065Ba Further company coverage: STXS.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shield Therapeutics
See all newsBrief: Shield Therapeutics To Assume Full Commercial Control Of ACCRUFeR In US
Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US
Shield Therapeutics - Interim results for the six months ended 30 Jun 26
Brief: Shield Therapeutics Says On Track For Profitability In 2026; Appoints Michael Jensen As CFO
Shield Therapeutics - Q2 and H1 2026 Trading Update